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Abstract

Furanodiene is a bioactive sesquiterpene isolated from the spice-producing
Curcuma wenyujin plant (Y.H.Chen et C.Ling) (C. wenyujin), which is a commonly
prescribed herb used in clinical cancer therapy by modern practitioners of traditional
Chinese medicine. Previously, we have shown that furanodiene inhibits breast cancer
cell growth both in vitro and in vivo, however, the mechanism for this effect is not yet
known. In this study, therefore, we asked (1) whether cultured breast cancer cells
made resistant to chemotherapeutic agent doxorubicin (DOX) via serial selection
protocols are susceptible to furanodiene’s anticancer effect, and (2) whether
AMP-activated protein kinase (AMPK), which is a regulator of cellular energy
homeostasis in eukaryotic cells, participates in this effect.
We show here (1) that doxorubicin-resistant MCF-7 (MCF-7/DOXR) cells treated
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with furanodiene exhibit altered mitochondrial function and reduced levels of ATP
content, resulting in apoptotic cell death, and (2) that AMPK is central to this effect.

phosphorylation of AMPK and AMPK pathway intermediates, ACLY and GSK-3β,
suggesting that furanodiene reduces mitochondrial function and cellular ATP levels by
way of AMPK activation. Finally, we find that the cell permeable agent and AMPK
inhibitor compound C (CC), abolishes furanodiene-induced anticancer activity in
these MCF-7/DOXR cells, with regards to cell growth inhibition and AMPK
activation;

in

contrast,

(5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside,

AICAR
acadesine),

an

AMPK

activator, augments furanodiene-induced anticancer activity. Furthermore, specific
knockdown of AMPK in MCF-7/DOXR cells protects these cells from
furanodiene-induced cell death.
Taken together, these findings suggest that AMPK and its pathway intermediates
are promising therapeutic targets for treating chemoresistant breast cancer, and that
furanodiene may be an important chemical agent incorporated in next-generation
chemotherapy protocols.
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furanodiene;

mitochondrial
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metabolic
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reprogramming



This is the first study reporting that furanodiene exhibits anticancer effects on
doxorubicin-induced chemoresistant tumor cells.



This is the first study reporting that furanodiene alters mitochondrial function in
an AMPK-dependent manner.



The AMPK-mediated effects of furanodiene, documented here, suggest that
doxorubicin-induced chemoresistance can be abolished, by furanodiene or other
compounds that activate AMPK, in breast cancer cells.

1. Introduction

Breast cancer is the most frequently diagnosed tumor type in women worldwide.
Despite advances in our understanding to better prevent, diagnose, and treat the
disease, breast cancer still represents a major cause of mortality as standard treatment
options, including surgical excision of tumor tissue and chemotherapy, have yet to
adapt to the development of multidrug resistance (MDR). This therapeutic mismatch
commonly results in chemotherapy failure, tumor recurrence and further progression,
leading to outcomes with low prognosis1.
Cancer cells are metabolically distinct from normal cells upon transformation.
The new metabolic signature is commonly referred to as the ‘Warburg Effect,’ which
4
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is characterized by enhanced glycolysis and reduced mitochondrial oxidation2. Other
changes associated with the Warburg Effect include the increased expression and
activity of ATP-binding cassette transporters (ABC transporters), which has been
shown to contribute to drug efflux and promote chemoresistance3,

4

, and

downregulated AMP-activated kinase (AMPK) activity, an adaptive response to
promote tumor cell survival under the Warburg conditions of increased glycolysis,
and decreased mitochondrial ATP production5. While the molecular mechanisms of
MDR onset are still unclear, there is evidence that (1) treatment with
chemotherapeutic drugs increases the expression of several ABC transporters
associated with MDR6, and that (2) across many different MDR cell-lines, including
MCF-7, MDR cells clearly overexpressed ABC transporter genes in comparison with
their drug-sensitive parental lines7. This suggests that global metabolic changes in
cancer, such as those mediated by the Warburg Effect, maybe potentially influence the
development of MDR, and can be investigated to identify promising therapeutic
targets for treating chemoresistant breast cancer.
AMP-activated protein kinase (AMPK), an energy sensor presents in healthy
eukaryotic cells, is also an important enzymatic control of energy homeostasis during
cancer cell transformation and proliferation8. This enzyme is activated by intracellular
conditions that increase AMP to ATP and ADP to ATP ratios9, and thus is sensitive to
metabolic stresses, such as hypoxia and glucose starvation, wherein the precipitated
redox dysregulation and mitochondrial dysfunction can cause abnormal ATP
consumption and suppress mitochondrial ATP synthesis, leading to AMPK activation.
AMPK activation inhibits anabolic metabolism, including gluconeogenesis and fatty
acid synthesis, and stimulates catabolic metabolism, including fatty acid oxidation10-13,
while enhancing mitochondrial oxidation and biogenesis to exert anti-Warburg and

5
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anti-proliferative effects in lymphomas14. Therefore, AMPK performs a central role in
regulating cell metabolism.

metabolism inhibition, wherein ATP-consuming processes are switched off.
Paradoxically, cancer cells, toward promoting their adaptation to metabolic stresses,
hijack AMPK activation. This counterintuitive, controversial role of AMPK has been
studied and discussed in detail15, and we now know that AMPK plays many roles in
tumor initiation, growth and spread. For example, AMPK-dependent autophagy of
pancreatic cancer cells, leading to cell death, can be induced by cannabinoid
treatment16. As noted above, AMPK has been shown to maintain nicotinamide
adenine dinucleotide phosphate (NADPH) levels, exploiting the Warburg Effect in
favor of tumor cell survival under energy stress17. Loss of AMPK signaling
contributes to the Warburg Effect in H1299 non-small-cell lung tumor cells and
HCT116 colon cancer cells, and it also supports tumor growth in vivo14. In kidney
tumor cells grown under fumarate hydrate (FH) deficiency, AMPK-assisted p53 and
hypoxia-inducible factor 1α (HIF-1α) promote the Warburg Effect, contributing to
tumor growth18. In C4-2 prostate cancer cells, knockdown of AMPK by α1 shRNA
promotes cell proliferation and maintains the malignant phenotype in vitro19.
Agents that activate AMPK, such as OSU-53, are under investigation as a therapy
for triple-negative breast cancer20. The antidiabetic drug metformin has also been
examined for its anticancer properties, which include re-sensitizing acquired MDR
MCF-7/5-FU

and

innate

MDR

MDA-MB-231

breast

cancer

cells

to

chemotherapeutics21. This suggests that other activators of AMPK may have similar
anticancer effects.
Furanodiene is a bioactive sesquiterpene found abundantly in Curcuma wenyujin

6

Molecular BioSystems Accepted Manuscript

As noted above, AMPK activation is a normal compensatory response to anabolic

Page 7 of 44

Molecular BioSystems

7
(Y.H.Chen et C.Ling), a Chinese herb possessing anticancer properties. Curcuma
wenyujin is widely prescribed for clinical cancer therapy by modern practitioners of

approved by the State Food and Drug Administration (SFDA) as new second-class
drugs for cancer chemotherapy22, 23. Furanodiene, one of these isolates, exhibits a
variety

of

pharmacological

properties,

which

include

hepatoprotection,

anti-inflammation, anti-angiogenesis and anticancer effects, and its anti-proliferative
and pro-apoptotic effects have been studied in a variety of cancer cell lines (HepG2,
HL-60, HeLa, PC3, SGC-7901, HT-1080, MCF-7, MDA-MB-231, A549, NIH-H1299,
95-D)

24-30

. Work in our laboratory has shown that furanodiene inhibits the growth of

breast cancer cells in vitro and in vivo23, and that it enhances tamoxifen-induced
growth inhibition, in estrogen receptor alpha- (ERα-) positive breast cancer cells, in a
peroxisome proliferator-activated receptor γ (PPARγ) independent manner31. Work by
others has shown that furanodiene suppresses migration and invasion of metastatic
breast cancer cells in vitro32. In this study, therefore, we sought to identify
mechanisms underlying the effects of furanodiene on doxorubicin-induced
chemoresistant breast cancer MCF-7 cells. We hypothesized that AMPK activation is
involved in furanodiene-induced anticancer effects.

2. Materials and Methods

2.1. Reagents and Cell Culture

Furanodiene was purchased from the National Institutes for Food and Drug Control
7
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(Beijing, China). Doxorubicin (DOX) was obtained from Sigma-Aldrich (St. Louis,
USA). RPMI-1640 culture medium was purchased from Gibco (Maryland, USA).

(PS), and 0.25% (w/v) trypsin/1 mM EDTA were obtained from Invitrogen (Carlsbad,
USA). 3-[4, 5-Dimethyl-2-thiazolyl]-2, 5-diphenyltetrazolium bromide (MTT),
MitoTracker® Deep Red FM, propidium iodide (PI), and Annexin V/PI detection kits
were obtained from Molecular Probes (Eugene, USA). Radioimmunoprecipitation
assay (RIPA) lysis buffer was obtained from Beyotime (Shanghai, China). The ATP
colorimetric/fluorometric assay kit was obtained from Biovision (California, USA).
Primary antibodies against phosphor-ATP-Citrate Lyase (p-ACLY) (Ser455),
ATP-Citrate Lyase (ACLY), p-GSK-3β (Ser9), AMPKα, p-AMPKα (Thr172), HER2,
β-actin, and GAPDH, and the appropriate secondary antibodies, were purchased from
Cell Signaling (Danvers, USA).

The MCF-7 human breast cancer cell line was purchased from American Type Culture
Collection (USA). To induce doxorubicin resistance, these cells were cultured with
RPMI1640 medium containing fetal bovine serum (10%), penicillin (100 units/mL),
and streptomycin (100 µg/mL), at 37˚C in a humidified atmosphere of 5% CO2 in air.
Doxorubicin-resistance was established by stepwise exposure to increased
concentrations of doxorubicin, as described previously33.

8
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2.2. Mitochondrial Function Assay

overnight. Then, a 24-hour serum-free starvation was carried out to synchronize the
cell division in the cultures. Cells were treated with furanodiene (0, 50, 100 µM) or
doxorubicin (2 µM) for four hours, and then harvested, washed with PBS, and
re-suspended gently in serum-free RPMI 1640 medium with MitoTracker® Deep Red
probe (100 nM). Cells were protected from light, and exposed to the probe for 15
minutes at room temperature. Then, cells were refreshed with pre-warmed medium
and analyzed by flow cytometry (BD FACS CantoTM, BD Biosciences, San Jose,
USA).

2.3. ATP Production Assay

Cells were seeded in 60-mm Petri dishes at a density of 5×105/dish, allowed to adhere
overnight, and then treated with furanodiene (0, 50, 100 µM) or doxorubicin (2 µM)
for four hours. The cells were then lysed with assay buffer and prepared according to
the manufacturer’s instructions using 500 µg loading protein. Fluorescence (Ex/Em
535/587 nm) was measured using a SpectraMax M5 microplate reader (Molecular
Devices). Fluorescence was expressed as a percentage of the values in control
untreated cells.

9
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Cell number images were captured with a microscope (Olympus MVX10, Japan)
equipped with a digital camera (ColorView II, Soft Imaging System, Olympus) after
the indicated drug treatments, and cell numbers were quantitated under a 100×
magnification. Representative cell counts were based on at least three independent
experiments.

2.5. Cell Viability Assay

MCF-7 cell viability was measured by the MTT assay34. The cells were seeded in
96-well plates at density of 1×104/well, and allowed to adhere overnight. Then, a
24-hour serum-free starvation was carried out to synchronize cell division in the
cultures, before drug treatment with either doxorubicin or furanodiene for another 24
hours. When these cells are lysed, viable cells form formazan, which can be measured
spectrophotometrically at 570 nm. To the formazan measurement, we used a
SpectraMax M5 microplate reader (Molecular Devices). Cell viability was expressed
as a percentage of formazan absorbance relative to the formazan absorbance in
untreated control cells.

10
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2.6. Cell Cycle and Apoptosis Assay

furanodiene treatment (100 µM) for 24 hours, cells were harvested via centrifugation,
washed with ice-cold PBS, re-suspended in 70% (v/v) ice-cold ethanol for fixation,
and then kept at -20˚C overnight. The fixed cells were then incubated with a
propidium iodide (PI) staining solution (20 µg/mL PI, 8 µg/mL RNase), for 30
minutes in the dark. Apoptosis induced by furanodiene, in doxorubicin-resistant
MCF-7 (MCF-7/DOXR) cells, was determined by Annexin V/PI labeling according to
the manufacturer’s protocol (Invitrogen). Cell cycle distribution and apoptosis were
determined by flow cytometry (BD FACS CantoTM, BD Biosciences, San Jose, USA),
based on DNA content in the cells and the sub-G1 cell population, respectively. The
data were analyzed using Mod Fit LT software (version 3.0).

2.7. Western Blotting

For Western blotting, the cells were seeded in 25-cm2 flasks at a density of
1×106/flask. After cell adhesion, drug treatment was carried out for 24 hours, as
described above. Cell lysates were prepared and centrifuged for 20 minutes at 4˚C,
after which the total protein content was determined using a BCA protein assay
reagent kit. Equal amounts of total protein were loaded into the wells of SDS-PAGE

11
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(8%) gels and subjected to electrophoresis, after which the gels were transferred to
methanol-activated PVDF membranes. After a 1-hour blocking incubation in non-fat

(1:1000 dilution), followed by a 1-hour incubation in the secondary antibodies
(1:1000 dilution), at room temperature. Immunoreactive bands were visualized and
quantitated using an Enhanced Chemiluminescence (ECL) Western blotting detection
kit (Amersham). Band densitometry was normalized by either β-actin or GAPDH,
which were used as the loading controls.

2.8. Transfection and shRNA

Transfection with plasmids was performed as described previously 35. The AMPK
shRNA sequence was
5’-GATGATGTCAGATGGTGAATTTAAGTTCTCTAAATTCACCATCTGACATCA
TTT-3’. The target sequence
5’-GTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAAT
T-3’ was used as a non-silencing control. Doxorubicin-resistant cells were transfected
with shRNAs using Lipofectamine 2000, according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA, USA). After four hours of transfection, the cells were first
refreshed and then cultured in complete medium containing 10% fetal bovine serum,
100 units/mL penicillin, and 100 µg/mL streptomycin in 6-well plates, for a further 48

12
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hours, before furanodiene treatment, which was conducted as described above.

All data are expressed as the mean of at least three separately performed experiments,
plus or minus standard deviation. The significance of the differences was evaluated by
GraphPad Prism software (GraphPad Software, USA). Newman-Keuls multiple
comparison tests were performed for post hoc pairwise comparisons. p-values less
than 0.05 were considered as significance.

3. Results

3.1. Furanodiene suppresses mitochondrial function in doxorubicin-resistant
MCF-7 (MCF-7/DOXR) human breast cancer cells.

To assess the effect of furanodiene on mitochondrial function in MCF-7/DOXR cells,
these cells were treated with furanodiene in increased doses (0, 50, 100 µM) or with
doxorubicin (2 µM) for four hours. Flow cytometry analysis using MitoTracker®
Deep Red probe (100 nM) detected and quantitated differences in mitochondrial
function between control and treated cells, as shown in Fig. 1A, and differences in
mean fluorescence intensity (MFI) were assessed after normalizing treatment

13
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intensities to the untreated control, as shown in Fig. 1B. Mitochondrial functions of
doxorubicin-treated MCF-7/DOXR cells are not significantly different from those of

MFIs (Figs. 1A, 1B). This finding confirms that serial selection of cultured MCF-7
cells resistant to doxorubicin-induced apoptosis indeed produces MCF-7/DOXR cells,
at least with respect to mitochondrial function. These data also show that furanodiene
treatment significantly suppresses mitochondrial function, in a dose-dependent
fashion. Moreover, treatment with doxorubicin in these cultured MCF-7/DOXR cells
does not significantly affect cellular ATP content (measured using an ATP kit), further
confirming doxorubicin-resistance. In addition to its effect on mitochondrial function,
documented above, furanodiene treatment (for 24 hours at 50 or 100 µM)
significantly suppresses ATP content in treated cells, in a dose-dependent manner, as
shown in Fig. 1C.

3.2. Furanodiene regulates phosphorylation of AMPK pathway signaling
intermediates in MCF-7/DOXR human breast cancer cells.

Western blot assays were used to analyze MCF-7/DOXR cell lysates for their contents
of important AMPK pathway signaling intermediates, which include ATP citrate lyase
(ACLY), glycogen synthase kinase (GSK-3β), and AMP-activated protein kinase
(AMPKα), using β-actin protein levels as the loading control. Treatment with

14
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doxorubicin (for 24 hours at 2 µM) exhibits no effect on phosphorylated and
non-phosphorylated ACLY and GSK-3β levels, in MCF-7/DOXR cells, when

contrast, furanodiene treatment (for 24 hours at 50, 100 µM) of these cells
significantly induces AMPK phosphorylation, significantly inhibits both ACLY
phosphorylation and expression, and significantly inhibits GSK-3β phosphorylation,
in a dose-dependent manner.

3.3. Furanodiene and doxorubicin suppress mitochondrial function and induce
phosphorylation of AMPK in doxorubicin-sensitive MCF-7 (MCF-7/DOXS)
human breast cancer cells.

To assess the effect of furanodiene on mitochondrial function in MCF-7/DOXS cells,
these cells were treated with furanodiene in increased doses (0, 50, 100 µM) or
doxorubicin (2 µM) for four hours. Flow cytometry analysis using MitoTracker®
Deep Red probe (100 nM) detected and quantitated differences in mitochondrial
function between control and treated cells, as shown in Fig. 2A. From visual
inspection of Fig. 2A, mitochondrial function in treated MCF-7/DOXS cells is
suppressed by both furanodiene (dose-dependent) and doxorubicin, when compared to
the untreated control (reflected by similar MitoTracker® Deep Red MFIs). Fig. 2B
shows

significantly

decreased

ATP

content

in

both

furanodiene-

and

15
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doxorubicin-treated cells relative to the untreated controls (measured using an ATP
kit). Finally, both furanodiene and doxorubicin were observed to induce

Collectively, these observations further confirm that the parental MCF-7 line is
sensitive to both furanodiene and doxorubicin.

3.4. Furanodiene-induced cell growth inhibition is diminished in presence of the
AMPK inhibitor compound C (CC), but elevated in the presence of the AMPK
activator AICAR, for MCF-7/DOXR human breast cancer cells.

MCF-7/DOXR cells were treated for four hours, either with 2 µM of compound C
(CC),

an

AMPK

inhibitor,

or

with

(5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside,

50

µM
acadesine),

of
an

AICAR
AMPK

activator, alone or in combination with 100 µM of furanodiene. Figs. 3A and 3B show
that treatment of MCF-7/DOXR cells with AMPK inhibitor CC, used alone, enhances
mitochondrial function (reflected by an increase in MFI relative to the untreated
control), and increases ATP content, as shown in Fig. 3C. By contrast, treatment of
these cells with the AMPK activator AICAR, used alone, has no significant effect on
either mitochondrial function (Figs. 3A, 3B) or ATP content (Fig. 3C). The growth
inhibitory effects of furanodiene, and the effects of CC and AICAR, are also evident
by the striking alterations in cell numbers induced by these compounds when viewed

16
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under the microscope. Fig. 3D shows that furanodiene treatment (for eight hours at
100 µM) decreases the number of MCF-7/DOXR cells significantly, in comparison to

AMPK, attenuates the reduction in cell number, while AICAR treatment (50 µM)
enhances it.

3.5. AMPK activation induced by furanodiene is diminished in presence of CC,
but strengthened in the presence of AICAR

AMPK activation induced by furanodiene treatment (for 24 hours at 100 µM) is
diminished in the presence of CC, but strengthened in the presence of AICAR in
MCF-7/DOXR cells (Fig. 3E). Further evidence pointing to AMPK as the central
signaling intermediate is also shown in Fig. 3E. The γ-H2A.X biomarker is a reliable
immunohistochemical marker for DNA double strand breaks and genomic instability.
Furanodiene increases γ-H2A.X expression in these cells, unless they are pro-treated
with CC (which decreased furanodiene-induced γ-H2A.X expression) or AICAR
(which further enhanced furanodiene-induced γ-H2A.X expression). Of note: in the
absence of furanodiene treatment, neither CC nor AICAR treatment of the cells
affects expression of γ-H2A.X.

3.6. Knockdown of AMPK reverses the effect of furanodiene on mitochondrial

17
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function and metabolic signaling

AMPK is strong in MCF-7/DOXR cells. By contrast, knockdown of AMPK
expression does not affect HER2 or β-actin expression (Fig. 4A), although
AMPK-knockdown cells are still resistant to doxorubicin, with an IC50 value of
66.57 µM (Fig. 4B). MCF-7/DOXR cells transfected with shAMPK are subsequently
much less sensitive to furanodiene-induced suppression of ATP content (Fig. 4C) and
mitochondrial function (Figs. 5A, B) than the cells transfected with shControl. In the
same cells, however, knockdown of AMPK expression significantly attenuates
furanodiene-induced AMPK phosphorylation and γ-H2A.X up-regulation. There is no
significant difference in HER2 expression, ACLY phosphorylation, ACLY expression,
GSK-3β phosphorylation, GSK-3β expression induced by furanodiene in cells
transfected with shControl when compared to cells transfected with shAMPK (Fig.
5C).

3.7. Knockdown of AMPK attenuates the pro-apoptotic and the growth
inhibitory effects of furanodiene

Figs. 5D and 5E show that knockdown of AMPK expression in MCF-7/DOXR cells
attenuates furanodiene-induced sub-G1 phase arrest. In addition, measurement of

18
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apoptosis in the cells confirms that knockdown of AMPK expression attenuates the
pro-apoptotic effect of furanodiene (Figs. 6A, 6B). Finally, knockdown of AMPK

induced in these cells by furanodiene (Fig. 6C). This effect is confirmed by cell
viability comparisons using the MTT assay, as shown in Fig. 6D.

4. Discussion and Conclusion

Many in vitro and in vivo studies have documented the anticancer effects of
furanodiene, but none yet have tested the hypothesis that furanodiene-induced
anticancer effects are mediated by AMPK23, 27, 36. In this report, we demonstrate that
breast cancer cell chemoresistance to doxorubicin, which can be induced in the
well-characterized MCF-7 breast cancer cell line, is still sensitive to furanodiene
treatment via the AMPK pathway (Fig. 7).

Metabolic reprogramming, a mechanism for tumor growth commonly known as the
Warburg Effect, and chemoresistance onset in cancer has been studied extensively by
others37, 38. Our approach applied a more specific working hypothesis, and sought to
identify the mechanisms behind restored treatment efficacy in breast cancer cells with
induced chemoresistance. The results shown here demonstrate for the first time that
furanodiene alters mitochondrial function and intracellular ATP levels, and that it

19
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exerts anticancer effects in induced-MCF-7/DOXR breast cancer cells via AMPK
pathway signaling. Furthermore, we show that this effect of furanodiene affects the

signaling, include ACLY, GSK-3β, γ-H2A.X, and HER2.

ACLY is a cytoplasmic enzyme that aids de novo fatty acid synthesis by generating
acetyl CoA, and its inhibition suppresses tumor cell growth in a subset of cancer
types39-44. Work by others has shown that ACLY depletion induces AMPK
phosphorylation, and the phosphorylation levels were found to correlate significantly
with levels of oxidative DNA damage in vitro and in vivo, linking AMPK
phosphorylation with cellular ROS levels45-47. Fig. 1D provides preliminary evidence
that furanodiene may inhibit ACLY.

The GSK-3β molecule plays dual functional roles in tumorigenesis, acting as a tumor
suppressor in some tumor types but promoting the growth and development of others
48, 49

, and it associates with AMPK-β, the regulatory subunit of AMPK 50. By showing

that

furanodiene

inhibits

GSK-3β

phosphorylation

and

induces

AMPK

phosphorylation in Fig. 1D, we provide further evidence that furanodiene is an
AMPK activator, and that AMPK is tightly linked with ACLY and GSK-3β pathway
intermediates in establishing chemoresistance in tumor cells (Fig. 5C).

20

Molecular BioSystems Accepted Manuscript

levels and functions of important intermediate factors involved in AMPK pathway

Page 21 of 44

Molecular BioSystems

21

Other AMPK pathway intermediates have been shown to regulate cell death. AMPK
activation is correlated with suppression of HER2 activity, which precedes

its protein, are specific pathological markers in certain human breast cancers, and
work is underway in many laboratories toward targeting HER2 for chemotherapy52. In
our experimental model, we find that HER2 is downregulated by furanodiene, and
that this downregulation is still robust even in the presence of CC or AICAR, which
down- and up-regulates AMPK activation, respectively (Fig. 3E). In addition, we
demonstrate

that

knockdown

of

AMPK

expression

fails

to

reverse

furanodiene-induced HER2 regulation (Fig. 3C). The results suggest that HER2
might be an upstream factor of AMPK in the anticancer effects of furanodiene (Fig.
7).

Still other AMPK pathway intermediates are involved with DNA damage repair. For
example, γ-H2A.X is phosphorylated in an AMPK-dependent manner, leading to
direct transcriptional and chromatin regulator pathways leading to cellular adaptation
to stress53. In Fig. 3E, the results show that furanodiene action on γ-H2A.X is
involved in its effects on AMPK phosphorylation levels.

Compound C (CC) is a pyrazolopyrimidine derivative that acts as a permeable,
reversible and specific AMPK inhibitor, while AICAR is a specific cell-permeable
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commitment to cell death51. Amplification of the gene HER2, and overexpression of
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activator of AMPK. We show here that that AICAR reinforces AMPK activation by
furanodiene, and that CC counteracts this effect of furanodiene, by treating

assessing the metabolic impact on these cells using various assays of mitochondrial
function, ATP content, cell count and AMPK phosphorylation.

During apoptosis, γ-H2A.X phosphorylation is followed by formation of
double-strand breaks, and its accumulation in cells often documents and quantitates
DNA damage leading to apoptosis54-56. Our results show that γ-H2A.X is upregulated
by furanodiene, and that this effect is opposed by CC and shAMPK but assisted by
AICAR (Fig. 3E). These results confirm that furanodiene inhibits MCF-7 cell growth
via increasing cell apoptosis, by way of AMPK, in these cells.

To further confirm that AMPK activation is a direct effect of furanodiene in
chemoresistant cancer cells, we transfected MCF-7 cells with shAMPK, to knock
down AMPK expression, and then subjected the cells to the aforementioned
furanodiene treatment protocol. As expected, our results showed that knockdown of
AMPK expression attenuates mitochondrial function suppression, pro-apoptosis, cell
growth suppression and cell viability reduction induced by furanodiene. These
alterations in mitochondrial function after AMPK knockdown demonstrate that
furanodiene (a) inhibits cell growth (Figs. 6C, 6D) likely through increasing cell
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MCF-7/DOXR cells with furanodiene and these other agents, alone or together and
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apoptosis (Figs. 5D, 5E, 6A, 6B), and (b) regulates tumor metabolic reprogramming
in an AMPK-dependent manner (Figs. 4C, 5B, 5C).

Taken together, we show here that furanodiene inhibits cancer cell growth via the
AMPK pathway, and causes cell apoptosis via metabolic regulation in chemoresistant
MCF-7 breast cancer cells. This is the first investigation of the anticancer potential of
furanodiene in chemoresistant cancer cells, and the first investigation to link a
relatively new anti-cancer drug, furanodiene, to a relatively old hypothesis for cancer
treatment, through targeting tumor metabolism. Finally, this is the first study that links
AMPK activation to the effects of furanodiene on cancer cells. We suggest that
furanodiene is an anti-cancer agent that may play an important role in addressing the
problem of multidrug resistance (and loss of chemotherapeutic efficacy) via
intervention in cancer metabolic reprogramming.

In addition, it has been shown that the level of glucose concentration within the tumor
microenvironment is a critical variable in cancer response and treatment outcomes.
Specifically, only under glucose withdrawal stress was metformin activation of
AMPK lethal to breast cancer cells, by circumventing HER2 oncogenic protection of
these cells from glucose-deprivation apoptosis57. Conversely, high concentrations of
glucose (4500 and 9000 mg/L) promote chemoresistance in SGC-7901 gastric cancer
cells in vitro, and in gastric cancer patients with type 2 diabetes in vivo58. Of special
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interest for future investigation is (a) whether AMPK activation by different stimuli,
e.g., glucose starvation (2-deoxyglucose) or metformin, will share similar treatment

cancer cells, and (b) where the pathway signals activating AMPK can be integrated
within the cell across different stimuli to produce synergistic anticancer effects.
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AMPK (AMP-activated protein kinase); ATP (Adenosine-5'-triphosphate); ACLY
(ATP-Citrate Lyase); GSK-3β (Glycogen synthase kinase-3β); MDR (Multidrug

dinucleotide phosphate); FH (fumarate hydratase); HIFα (hypoxia-inducible factor α);
LDHA (Lactate dehydrogenase A); Nampt (Nicotinamide phosphoribosyltransferase);
TPA (12-O-tetradecanoylphorbol-13-acetate); ER (Estrogen receptor); PPARγ
(peroxisome

proliferator-activated

receptor

γ);

FUR

(Furanodiene);

DOX

(Doxorubicin); FBS (Fetal bovine serum); PBS (Phosphate-buffered saline); PS
(Penicillin-streptomycin); EDTA (Ethylenediaminetetraacetic acid); MTT (3-[4,
5-Dimethyl-2-thiazolyl]-2, 5-diphenyltetrazolium bromide); PI (Propidium iodide);
RIPA

(Radioimmunoprecipitation

assay);

SDS-PAGE

(Sodium

dodecyl

sulphate-Polyacrylamide gel electrophoresis); PVDF (Polyvinylidene fluoride); CC
(Compound C); AICAR (5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside,
acadesine)
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Figure Legends

Fig. 1. Effects of furanodiene (FUR or F) on mitochondrial function in
doxorubicin-resistant MCF-7 (MCF-7/DOXR) human breast cancer cells.
MCF-7/DOXR cells were treated with furanodiene in increased doses (0, 50, 100 µM)
or with doxorubicin (2 µM). (A) Mitochondrial functions of these MCF-7/DOXR cells
were assessed after four hours by means of the mean fluorescence intensity (MFI)
obtained via flow cytometry analysis (100 nM MitoTracker® Deep Red probe,
incubated for 15 min). (B) MFIs of cells treatment groups were normalized to and
compared with the MFI of untreated control. (C) ATP content was quantitated using
an ATP kit following the manufacturer’s protocol. Fluorescence intensities were
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determined using 500 µg loading protein, and was normalized to and compared with
the fluorescence intensity of the untreated control. (D) Cell lysates were analyzed for

glycogen synthase kinase (GSK-3β), and AMP-activated protein kinase (AMPKα)
using Western blot assay, with β-actin protein levels serving as the loading control.
Data represent the mean ± S.E.M of three independent experiments. *P < 0.05, **P <
0.01 and ***P < 0.001.

Fig. 2. Effects of furanodiene (FUR or F) on mitochondrial function in
doxorubicin-sensitive MCF-7 (MCF-7/DOXS) human breast cancer cells.
MCF-7/DOXS cells were treated with furanodiene in increased doses (0, 50, 100 µM)
or with doxorubicin (2 µM). (A) Mitochondrial functions of these MCF-7/DOXS cells
were assessed after four hours by means of the mean fluorescence intensity (MFI)
obtained via flow cytometry analysis (100 nM MitoTracker® Deep Red probe,
incubated for 15 min). (B) ATP content was quantitated using an ATP kit following
the manufacturer’s protocol. Fluorescence intensities were determined using 500 µg
loading protein, and was normalized to and compared with the fluorescence intensity
of the untreated control. (C) Cell lysates were analyzed for their contents of
phosphorylated and expression levels of AMP-activated protein kinase (AMPKα)
using Western blot assay, with β-actin protein levels serving as the loading control.
Data represent the mean ± S.E.M of three independent experiments. *P < 0.05 and
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their contents of phosphorylated and expression levels of ATP citrate lyase (ACLY),
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***P < 0.001.

mitochondrial function in doxorubicin-resistant MCF-7 (MCF-7/DOXR) human
breast cancer cells. MCF-7/DOXR cells were pro-treated with either 2 µM of
compound C (CC), an AMPK inhibitor, or with 50 µM of AICAR (AI), an AMPK
activator, then treated with 100 µM of furanodiene. (A) Mitochondrial functions of
these MCF-7/DOXR cells were assessed after four hours by means of the mean
fluorescence intensity (MFI) obtained via flow cytometry analysis (100 nM
MitoTracker® Deep Red probe, incubated for 15 min). (B) MFIs of cells treatment
groups were normalized to and compared with those of their respective controls. (C)
ATP content was quantitated using an ATP kit following the manufacturer’s protocol.
Fluorescence intensities of treatment groups was normalized to and compared with
the fluorescence intensity of the untreated control. (D) Cell density was observed with
a light microscope under a 100× magnification and counted. All mean cell numbers
were normalized to the cell numbers in the field of view of the untreated control. (E)
Cell lysates were analyzed for their contents of human epidermal growth factor
receptor (HER2), phosphorylated AMP-activated protein kinase (p-AMPKα), and a
histone protein (γ-H2A.X) using Western blot assay, with GAPDH protein levels
serving as the loading control. Data represent the mean ± S.E.M of three independent
experiments. *P < 0.05 and **P < 0.01.

33

Molecular BioSystems Accepted Manuscript
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Fig. 4. Effects of furanodiene (FUR) on mitochondrial function alterations in

cancer cells.
MCF-7/DOXR cells were transfected with shRNA using Lipofectamine 2000 for four
hours, returned to culture for 48 hours. (A) Cell lysates from non-transfected,
transfected shControl, and AMPK-knockdown MCF-7/DOXR cells were harvested
and analyzed for their contents of AMPKα and HER2 using Western blot assay to
confirm the specificity and effectiveness the shRNA transfection procedure, with
β-actin protein levels serving as the loading control. (B) Non-transfected, transfected
shControl, and AMPK-knockdown MCF-7/DOXR cells were seeded in 96-well plates
at a density of 10,000/well, and then were treated with doxorubicin for 24 hours. Cell
viability was determined via MTT assay. (C) The ATP content of transfected
shControl and AMPK-knockdown MCF-7/DOXR cells treated for four hours with
furanodiene (100 µM) was quantitated using an ATP kit following the manufacturer’s
protocol. Fluorescence intensities of treatment groups were normalized to and
compared with the fluorescence intensity of untreated transfected shControl cells.
Data represent the mean ± S.E.M of three independent experiments. *P < 0.05.

Fig. 5. AMPK is a central mediator of furanodiene (FUR) anticancer effects in
the mitochondria of doxorubicin-resistant MCF-7 (MCF-7/DOXR) human breast
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AMPK-knockdown, doxorubicin-resistant MCF-7 (MCF-7/DOXR) human breast
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cancer cells.
MCF-7/DOXR cells were transfected with shRNA using Lipofectamine 2000 for four

(A) Mitochondrial functions of these MCF-7/DOXR cells were assessed after four
hours by means of the mean fluorescence intensity (MFI) obtained via flow cytometry
analysis (100 nM MitoTracker® Deep Red probe, incubated for 15 min). (B) The MFI
of AMPK-knockdown cells were compared with the MFI of the transfected shControl
cells. (C) Cell lysates were analyzed for their contents of phosphorylated and
expression levels of ATP citrate lyase (ACLY), glycogen synthase kinase (GSK-3β),
and AMP-activated protein kinase (AMPKα) using Western blot assay. Human
epidermal growth factor receptor (HER2) and histone protein (γ-H2A.X) were also
analyzed. GAPDH protein levels served as the loading control. (D) Cell cycle
distributions were determined after 24-hour furanodiene treatment using flow
cytometry analysis of cell DNA content (stained with propidium iodide). (E) The
percentages of sub-G1 phase cells (out of total cells) were determined for each of the
transfected shControl and AMPK-knockdown experiment conditions, and then these
were compared statistically. Data expressed as mean ± S.E.M of three independent
experiments. **P < 0.01.

Fig. 6. Furanodiene (FUR)-induced cell apoptosis occurs via AMPK signaling in
doxorubicin-resistant MCF-7 (MCF-7/DOXR) human breast cancer cells.
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hours, returned to culture for 48 hours, and then treated with furanodiene (100 µM).
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MCF-7/DOXR cells were transfected with shRNA using Lipofectamine 2000 for four
hours, returned to culture for 48 hours, and then treated with furanodiene (100 µM).

analyzed by flow cytometry. (B) The percentages of late-stage apoptotic cells
(Annexin V and PI double-positive cells, Q2) and early-stage apoptotic cells (Annexin
V and PI double-positive cells, Q3) were calculated, and then these were compared
statistically. (C) Cell density was observed with a light microscope under a 400×
magnification. (D) Cells were seeded in 96-well plates at a density of 10,000/well,
and cell viability was determined via MTT assay. Data represent the mean ± S.E.M of
three independent experiments. *P < 0.05.

Fig.

7.

Furanodiene

(FUR)-induced

anticancer

mechanism

and

doxorubicin-resistant MCF-7 (MCF-7/DOXR) breast cancer cell outcomes.
AMPK is an important energy-sensing enzyme regulating many aspects of metabolic
reprogramming. Evidence exists that targeting AMPK may exert anti-Warburg and
anti-proliferative effects by enhancing mitochondrial oxidation and biogenesis. Using
the AMPK inhibitor compound C (CC), the AMPK gene silencer shAMPK, and the
AMPK activator AICAR, we demonstrated that the AMPK pathway is the essential
mechanism by which furanodiene induces its anticancer effect in MCF-7/DOXR
breast cancer cells. Important AMPK signaling pathway intermediates, including ATP
citrate lyase (ACLY) and glycogen synthase kinase (GSK-3β), are also inhibited by
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(A) Cells were probed with Annexin V (FITC-A) and PI (PE-A) dyes, and then
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furanodiene; whether by AMPK direct involvement has yet to be seen. Furanodiene is
also responsible for the robust downregulation of HER2 documented in these studies,
even in the presence of CC and AICAR. This is important because HER2 is a
pathological marker specific to some aggressive human breast cancers. This
preliminary evidence suggests that HER2 is an upstream factor that governs AMPK
activation in furanodiene-mediated anticancer activity.
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